ASC2ESCALATE: A US phase 2, single-arm, dose-escalation study of asciminib monotherapy in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) previously treated with 1 prior tyrosine kinase inhibitor (TKI) Meeting Abstract


Authors: Atallah, E. L.; Mauro, M. J.; Sasaki, K.; Levy, M. Y.; Koller, P. B.; Sadek, I.; Yang, D.; Ruckel-Kumar, J.; Khan, M. H.; Cortes, J. E.
Abstract Title: ASC2ESCALATE: A US phase 2, single-arm, dose-escalation study of asciminib monotherapy in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) previously treated with 1 prior tyrosine kinase inhibitor (TKI)
Meeting Title: 2023 ASCO Annual Meeting
Journal Title: Journal of Clinical Oncology
Volume: 41
Issue: 16 Suppl.
Meeting Dates: 2023 Jun 2-6
Meeting Location: Chicago, IL
ISSN: 0732-183X
Publisher: American Society of Clinical Oncology  
Date Published: 2023-06-01
Language: English
DOI: 10.1200/JCO.2023.41.16_suppl.TPS7082
PROVIDER: EBSCOhost
PROVIDER: cinahl
DOI/URL:
Notes: Meeting Abstract: TPS7082 -- Meeting was also available virtually -- Source: Cinahl
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Michael John Mauro
    267 Mauro